Valuation: Verastem, Inc.

Market Cap 697M 620M 578M 527M 994M 67.04B 1B 7B 2.71B 34.27B 2.62B 2.56B 110B P/E 2026 *
-4.68x
P/E 2027 * -6.61x
Enterprise Value 739M 657M 613M 559M 1.05B 71.07B 1.06B 7.42B 2.87B 36.33B 2.78B 2.72B 117B EV / Sales 2026 *
6.35x
EV / Sales 2027 * 3.85x
Free-Float
98.98%
Yield 2026 *
-
Yield 2027 * -
09-28 Verastem Oncology Announces Publication Of Two-Year Long-Term Results From Phase 2 RAMP 201 Study Evaluating AVMAPKI FAKZYNJA CO-PACK In Recurrent Low-Grade Serous Ovarian Cancer CI
09-18 Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says MT
09-17 Wolfe Research Initiates Verastem at Outperform MT
09-14 RTW Biotech NAV rises 15% as public investments drive returns AN
09-08 Verastem Oncology Unveils New Clinical Data Highlighting The Best-In-Class Potential Of VS-7375, An Oral KRAS G12D (ON/OFF) Inhibitor Across Pancreatic, Lung, And Colorectal Cancers CI
08-11 Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating MT
08-07 Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million CI
08-06 Verastem, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-28 Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer CI
07-22 Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer CI
07-07 RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating MT
06-29 Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell Small Cap Comp Value Benchmark CI
1 day-2.53%
1 week-0.52%
Current month-4.35%
1 month-3.99%
3 months+71.11%
6 months+36.77%
Current year-0.26%
1 week 7.39
Extreme 7.39
8.4
1 month 7.2
Extreme 7.195
8.64
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 31/07/2023
Director of Finance/CFO 39 30/10/2022
Chief Tech/Sci/R&D Officer - 17/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 31/07/2023
Director/Board Member 69 02/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/26 Sell

Chief Financial Officer

-55 0.0001%
03/08/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/05/26 Free

Director

108,000 0.1229%
Change 5-day change 1-year change 3-year change Capi.($)
-2.53%-0.52%-14.35%-1.79% 697M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.46%-0.58%+47.51%+108.07% 39.12B
Weighted average by Cap. +0.12%-0.84%+58.63%+129.67%

Financials

2026 *2027 *
Net sales 116M 103M 96.54M 87.99M 166M 11.19B 167M 1.17B 453M 5.72B 437M 428M 18.36B 181M 161M 150M 137M 258M 17.41B 261M 1.82B 704M 8.9B 680M 665M 28.56B
Net income -166M -147M -138M -125M -236M -15.95B -239M -1.66B -645M -8.15B -623M -609M -26.16B -157M -140M -130M -119M -224M -15.1B -226M -1.58B -611M -7.72B -590M -577M -24.77B
Net Debt 41.9M 37.23M 34.75M 31.67M 59.73M 4.03B 60.29M 420M 163M 2.06B 157M 154M 6.61B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
02/10/26 US$7.700 -2.53% 4,071,838
01/10/26 US$7.900 -1.86% 1,762,500
30/09/26 US$8.050 +1.64% 1,568,537
29/09/26 US$7.920 +1.93% 2,677,180
28/09/26 US$7.770 +0.39% 1,260,637
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.700USD
Average target price
14.67USD
Spread / Average Target
+90.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock